Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences (NASDAQ: ANIX) has announced the treatment of the second patient in the fourth cohort of its Phase 1 clinical trial for ovarian cancer CAR-T therapy. The trial, conducted in partnership with Moffitt Cancer Center, is evaluating a novel treatment targeting the follicle-stimulating hormone receptor (FSHR).
Patients in the fourth cohort are receiving 3 million CAR-positive cells per kilogram of body weight, a 30-fold increase from the initial dose. Notably, no dose-limiting toxicities (DLTs) have been observed in this cohort. The study focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy, aiming to evaluate safety, determine maximum tolerated dose, and monitor clinical activity.
Anixa Biosciences (NASDAQ: ANIX) ha comunicato di aver trattato il secondo paziente nel quarto cohort del suo trial clinico di Fase 1 sulla terapia CAR-T per il cancro ovarico. Lo studio, condotto in collaborazione con il Moffitt Cancer Center, valuta un nuovo approccio terapeutico che prende di mira il recettore dell'ormone follicolo-stimolante (FSHR).
I pazienti del quarto cohort ricevono 3 milioni di cellule CAR-positive per chilogrammo di peso corporeo, un aumento di 30 volte rispetto alla dose iniziale. 脠 importante sottolineare che in questo cohort non sono state osservate tossicit脿 dose-limite (DLT). Lo studio riguarda donne adulte con carcinoma ovarico recidivante che hanno progredito dopo almeno due linee di terapia precedenti, con l'obiettivo di valutare la sicurezza, determinare la dose massima tollerata e monitorare l'attivit脿 clinica.
Anixa Biosciences (NASDAQ: ANIX) ha anunciado el tratamiento del segundo paciente en la cuarta cohorte de su ensayo cl铆nico de Fase 1 para la terapia CAR-T contra el c谩ncer de ovario. El ensayo, realizado en colaboraci贸n con el Moffitt Cancer Center, est谩 evaluando un novedoso tratamiento dirigido al receptor de la hormona estimulante del fol铆culo (FSHR).
Los pacientes de la cuarta cohorte est谩n recibiendo 3 millones de c茅lulas CAR-positivas por kilogramo de peso corporal, un incremento de 30 veces respecto a la dosis inicial. Cabe destacar que en esta cohorte no se han observado toxicidades limitantes de la dosis (DLT). El estudio se centra en mujeres adultas con c谩ncer de ovario recurrente que han progresado tras al menos dos l铆neas de tratamiento previas, con el objetivo de evaluar la seguridad, determinar la dosis m谩xima tolerada y monitorizar la actividad cl铆nica.
Anixa Biosciences (NASDAQ: ANIX)電� 雮滌唽鞎� CAR-T 旃橂鞝滌潣 1靸� 鞛勳儊鞁滍棙 雱� 氩堨Ц 旖旐樃韸胳棎靹� 霊� 氩堨Ц 頇橃瀽鞐愱矊 韴棳毳� 鞕勲頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 氤� 鞛勳儊鞚� Moffitt Cancer Center鞕�鞚� 順戨牓鞙茧 歆勴枆霅橂┌ 雮滍彫鞛愱饭順鸽ゴ氇� 靾橃毄觳�(FSHR)毳� 響滌爜鞙茧 頃橂姅 鞁犼窚 旃橂氩曥潉 韽夑皜頃橁碃 鞛堨姷雼堧嫟.
雱� 氩堨Ц 旖旐樃韸胳潣 頇橃瀽霌れ潃 觳挫 1kg雼� CAR 鞏戩劚 靹疙彫 300毵� 臧�毳� 韴棳氚涥碃 鞛堨溂氅�, 鞚措姅 齑堦赴 鞖╇焿氤措嫟 30氚� 歃濌皜頃� 靾橃箻鞛呺媹雼�. 欤茧頃� 鞝愳潃 鞚� 旖旐樃韸胳棎靹� 鞖╇焿 鞝滍暅 霃呾劚(DLT)鞚� 甏�彀半悩歆� 鞎婌晿雼る姅 瓴冹瀰雼堧嫟. 氤� 鞐瓣惮電� 斓滌唽 霊� 彀 鞚挫儊鞚� 旃橂 頉� 歆勴枆霅� 鞛皽靹� 雮滌唽鞎� 靹膘澑 鞐劚霌れ潉 雽�靸侅溂搿� 鞎堨爠靹� 韽夑皜, 斓滊寑 項堨毄 鞖╇焿 瓴办爼 氚� 鞛勳儊鞝� 頇滌劚鞚� 氇媹韯半頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Anixa Biosciences (NASDAQ: ANIX) a annonc茅 le traitement du deuxi猫me patient dans la quatri猫me cohorte de son essai clinique de phase 1 pour la th茅rapie CAR-T contre le cancer de l'ovaire. L'茅tude, men茅e en partenariat avec le Moffitt Cancer Center, 茅value un nouveau traitement ciblant le r茅cepteur de l'hormone folliculo-stimulante (FSHR).
Les patientes de la quatri猫me cohorte re莽oivent 3 millions de cellules CAR-positives par kilogramme de poids corporel, soit une augmentation par 30 par rapport 脿 la dose initiale. Il est notable qu'aucune toxicit茅 limitant la dose (DLT) n'a 茅t茅 observ茅e dans cette cohorte. L'茅tude porte sur des femmes adultes atteintes d'un cancer de l'ovaire r茅current ayant progress茅 apr猫s au moins deux lignes de traitement ant茅rieures, et vise 脿 茅valuer la s茅curit茅, d茅terminer la dose maximale tol茅r茅e et surveiller l'activit茅 clinique.
Anixa Biosciences (NASDAQ: ANIX) hat die Behandlung des zweiten Patienten in der vierten Kohorte ihrer Phase-1-Studie zur CAR-T-Therapie bei Eierstockkrebs bekanntgegeben. Die Studie, die in Zusammenarbeit mit dem Moffitt Cancer Center durchgef眉hrt wird, pr眉ft eine neuartige Therapie, die auf den follikelstimulierenden Hormonrezeptor (FSHR) abzielt.
Patienten der vierten Kohorte erhalten 3 Millionen CAR-positiver Zellen pro Kilogramm K枚rpergewicht, was einer 30-fachen Erh枚hung gegen眉ber der Anfangsdosis entspricht. Bemerkenswert ist, dass in dieser Kohorte keine dosislimitierenden Toxizit盲ten (DLTs) beobachtet wurden. Die Studie richtet sich an erwachsene Frauen mit rezidivierendem Eierstockkrebs, die nach mindestens zwei vorherigen Therapielinien progredient sind, und hat zum Ziel, Sicherheit, maximale vertr盲gliche Dosis und klinische Aktivit盲t zu bewerten.
- No dose-limiting toxicities observed even at 30x initial dose level
- Therapy continues to demonstrate favorable safety profile at higher doses
- Early indications show potential efficacy signals
- Still in early Phase 1 trial stage with limited patient data
- Efficacy data not yet conclusively demonstrated
Insights
Anixa's ovarian cancer CAR-T therapy progresses to higher dosing with continued favorable safety profile, potentially addressing a critical unmet need.
Anixa's CAR-T clinical trial for recurrent ovarian cancer has reached a significant milestone with the treatment of the second patient in the fourth cohort. This cohort is receiving 3 million CAR-positive cells per kilogram - a substantial
The trial targets the follicle-stimulating hormone receptor (FSHR), which shows a highly selective expression pattern: present on ovarian cells, tumor vasculature, and certain cancer cells, but critically absent in healthy tissue. This selectivity is essential for minimizing off-target effects that plague many oncology treatments.
For context, recurrent ovarian cancer represents a significant therapeutic challenge with limited effective options after multiple treatment failures. Patients enrolled in this trial have progressed after at least two prior therapies, placing them in a difficult-to-treat population with poor prognosis.
While efficacy data isn't detailed in this announcement (appropriate for an early Phase 1 trial primarily assessing safety), the mention of "early indications of potential efficacy" suggests some preliminary signals of therapeutic benefit. The ability to safely escalate to substantially higher doses improves the probability of achieving therapeutic concentrations necessary for clinical benefit.
The involvement of Moffitt Cancer Center and the technology's origin from The Wistar Institute adds credibility to this program, representing collaboration between academic innovation and clinical development.
Fourth Cohort Receiving 30x Initial Dose with No聽Dose-Limiting Toxicities Observed to Date
Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight鈥攔epresenting a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities (DLTs) have been observed in the fourth cohort.
Anixa's proprietary CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which preclinical research indicates is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells鈥攂ut not in healthy tissue. The ongoing first-in-human clinical trial ()聽is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity.
"Our therapy continues to demonstrate a favorable safety profile, even at significantly higher cell doses," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "While this study is primarily designed to assess safety, we remain encouraged by early indications of potential efficacy as the trial progresses."
Anixa's CAR-T technology was invented by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. The ongoing clinical trial is being conducted at Moffitt under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program. Anixa holds an exclusive worldwide license to the FSHR-targeting CAR-T technology from The Wistar Institute.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit 聽or follow Anixa on , , and .
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
View original content to download multimedia:
SOURCE Anixa Biosciences, Inc.
FAQ
What is the current status of Anixa Biosciences' ovarian cancer CAR-T trial?
How does Anixa's CAR-T therapy for ovarian cancer work?
Who is eligible for Anixa's ovarian cancer CAR-T clinical trial?
What are the main objectives of Anixa's Phase 1 CAR-T trial?
Where is Anixa's ovarian cancer CAR-T trial being conducted?
